Shopping Cart
Remove All
Your shopping cart is currently empty
MSC-4381 (MCT4-IN-1) is an orally available and selectively modeled highly potent inhibitor of monocarboxylic acid transporter protein 4 (MCT4/SLC16A3) with potential anticancer and antitumor activity for the study of osteosarcoma.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $64 | - | In Stock | |
| 5 mg | $156 | - | In Stock | |
| 10 mg | $239 | - | In Stock | |
| 25 mg | $413 | - | In Stock | |
| 50 mg | $579 | 7-10 days | 7-10 days | |
| 100 mg | $828 | 7-10 days | 7-10 days | |
| 200 mg | $1,090 | 7-10 days | 7-10 days | |
| 1 mL x 10 mM (in DMSO) | $185 | - | In Stock |
| Description | MSC-4381 (MCT4-IN-1) is an orally available and selectively modeled highly potent inhibitor of monocarboxylic acid transporter protein 4 (MCT4/SLC16A3) with potential anticancer and antitumor activity for the study of osteosarcoma. |
| In vitro | MCT4-IN-1 (compound 18n) inhibits lactate efflux in the MDA-MB-231 cell line with an IC50 of 1 nM. On-target activity was confirmed by fluorescence cross correlation spectroscopy (FCCS)[1] with a Ki of 11 nM[1]. |
| In vivo | When MCT4-IN-1 (30 mg/kg; oral; single dose) was used only in combination with MCT1/2 inhibitors, lactic acid accumulation in tumor cells was significant; MCT4-IN-1 (30 mg/kg/day; for 15 consecutive days) had no significant antitumor activity; MCT4-IN-1 (0.2 mg/kg; intravenous injection) had a T1/2 of 1 hour, a CL of 0.33 L/hkg, a Cmax of 489 ng/mL, and a Vss of 0.4 L/kg in mice[1]. |
| Synonyms | MSC4381, MSC 4381, MCT4-IN-1 |
| Molecular Weight | 537.97 |
| Formula | C26H20ClN3O6S |
| Cas No. | 2445185-57-7 |
| Smiles | CCOc1ccc(c2ncccc12)S(=O)(=O)Nc1ccc(Cl)cc1C#Cc1cnc(cc1OC)C(O)=O |
| Color | Yellow |
| Appearance | Solid |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 50 mg/mL (92.94 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween-80+45% Saline: 2.5 mg/mL (4.65 mM), Sonication is recommeded. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.